TELKONOL AM (Telmisartan (40mg) + Amlodipine (5mg))
-61%

TELKONOL AM (Telmisartan (40mg) + Amlodipine (5mg))

Original price was: ₹89.10.Current price is: ₹35.00.

Placeholder

Original price was: ₹89.10.Current price is: ₹35.00.

Add to cart
Buy Now
Category: Tag:

Telkonol-AM is a formulation that amalgamates Telmisartan (40 mg) with Amlodipine (5 mg), designed for efficient management of elevated blood pressure. Telmisartan functions as an angiotensin II receptor antagonist, which promotes the relaxation of blood vessels, thereby assisting in the reduction of blood pressure levels. On the other hand, Amlodipine acts as a calcium channel blocker; it works by obstructing the entry of calcium into the smooth muscle cells of both the heart and blood vessels. This mechanism not only enhances blood circulation but also contributes to a further decrease in blood pressure. Together, this synergistic combination of medications offers a robust approach to managing hypertension, which can significantly lower the risk of cardiovascular events such as heart attack and stroke. It is imperative for individuals with high blood pressure to adhere to their prescribed treatment plan, as this combination medication can facilitate better health outcomes and improve overall cardiovascular health. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.

Reviews

There are no reviews yet.

Be the first to review “TELKONOL AM (Telmisartan (40mg) + Amlodipine (5mg))”

Your email address will not be published. Required fields are marked *

Top